Peptistar has started operating Asahi Kasei's forward osmosis-membrane distillation (FO-MD) system at manufacturing scale, the companies announced. The system is deployed at Peptistar's facility to concentrate peptide active pharmaceutical ingredients (APIs) under mild conditions, a step that could improve efficiency in bioprocessing.
The FO-MD technology combines two separation processes: forward osmosis, which uses an osmotic pressure difference across a membrane to remove water, and membrane distillation, which leverages a vapor pressure difference. Together, they enable highly concentrated API solutions without the need for high temperatures that could degrade sensitive biologics.
No timeline was provided for broader commercialization or for regulatory filings related to drugs produced using this system. However, the deployment signals progress toward scalable production methods for peptide-based therapeutics, a growing segment in the pharmaceutical industry.
The announcement did not include specific financial terms, investment amounts, or stock movements. Peptistar, a peptide contract development and manufacturing organization, positions this technology to enhance its manufacturing capabilities, though the immediate impact on the company's market share or revenue remains unquantified.
Industry observers note that while integrated membrane systems offer efficiency gains, their adoption at scale requires significant capital investment and technical validation. The long-term cost benefits over traditional evaporation methods will depend on validation data from Peptistar's ongoing production runs.